Early detection of cancer increases the chance of survival and/or curative treatment. While this is true of all cancers, the World Health Organization puts emphasis on the value of early diagnosis in cancers of the breast, cervix, mouth, larynx, colon, rectum and skin. With particular focus on colorectal cancer, the third most common cancer in the United States, tests are expensive (up to $10,000 per patient), invasive and unpleasant, so most people don't take advantage of them.
After the age of 50, healthcare experts recommend a colonoscopy every five to ten years. Between these colonoscopies, people can use non-invasive tests that can sometimes determine the presence of cancer or even pre-cancers. The simple fact is that many people choose not to get invasive yet potentially life-saving colonoscopies at all.
There are two main tests for colorectal cancers in common clinical use, those which can detect cancer and polyps (such as colonoscopy or flexible sigmoidoscopy), which are highly invasive and expensive; and those that only detect cancer, such as the fecal occult blood tests (FOBTs) and fecal immunochemical test (NYSE:FIT).
FOBTs are used the most frequently used test, most likely because they are available for less than $25, and while a bit uncomfortable at the thought, are not physically invasive. However, these tests have a high false positive rate and low rate of detecting precancerous polyps. The FIT also detects blood in the stool, though it achieves a higher detection rate (37 percent) than FOBT. The downsides to this test are the approximately $100 cost and the fact that they may miss tumors that bleed in small amounts or not at all.
VolitionRx is a life sciences company focused on revolutionizing early detection, bringing to market its inexpensive, accurate, and easy-to-use cancer detection blood tests. The company's current focus is on the detection of colorectal cancer, though future plans call for expansion into detection of various other cancers as well.
The company's NuQ suite of products is based on proprietary Nucleosomics® technology, capable of measuring and identifying nucleosome structures in the blood. Based on this technology, VolitionRx is developing cancer screening tests and cancer diagnostic tests that require a very small amount of blood, can be turned around in a day, and are very cost effective. Following ongoing clinical trials and regulatory approval, the company plans to offer its tests for individualized cancers under the NuQ brand.
Human life is invaluable. Sadly, the price and invasiveness associated with colorectal cancer have cost many people their lives, resulting in a significant need for an improved alternative for colorectal cancer diagnoses. VolitionRx's blood-based approach to cancer tests are designed to make detection simple and affordable, revolutionizing cancer diagnosis.
For more information visit volitionrx.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com